Wall Street thinks that the clinical-stage biotech Celldex Therapeutics (NASDAQ: CLDX) could be a top-performing stock this year. The average 12-month price target on the stock, after all, implies a noteworthy 260% upside potential from …
Shares of the struggling small-cap biotech Celldex Therapeutics (NASDAQ: CLDX) finally showed some signs of life in November. Specifically, the biotech's stock rose by a healthy 27.6% last month, according to data from S&P Global …
Hampton, NJ-based Celldex Therapeutics, Inc. CLDX is a biopharmaceutical company developing immunotherapy technologies and other cancer-targeting biologics. The company is still in development stage and does not have any …
Celldex Therapeutics, Inc. CLDX is expected to report third-quarter 2016 results on Nov 3. Celldex’s performance has been encouraging with a three-quarter average positive surprise of 4.85%. In the last reported quarter, the company …
It looks like the heavy losses left bruises that the market isn't ready to forget, and the stock has yet to recover. That could change before too long. Celldex has another candidate approaching the finish line, called glemba, that is entirely …
The company is another Buy-rated stock at Jefferies, and its price target is $48. The consensus target is a huge $50.50. Dicerna closed Wednesday at $25.21. Celldex Therapeutics Inc. (NASDAQ: CLDX) has several pipeline …
Last week Healthcor disclosed a 5.86% stake in Celldex (CLDX) in a 13G filing. They paid around $3.30 per share on May 18th when the stock closed at $3.31. The stock currently trades at $3.70, giving Healthcor a 10+% return in less than …
... Therapeutics Inc. (CLDX) is a biotechnology company focused on developing antibody-based combination immunotherapies for the treatment of cancer and other difficult-to-treat diseases. RTTNews had alerted readers to the …
The stock imploded last year after brain cancer patients in the first control group tested against its former lead candidate outperformed historical survival data by a wide margin. When Rintega failed spectacularly, Celldex was lucky enough …